Opthea Ltd

NASDAQ:OPTUnited States

Opthea Limited is an Australia-based biotechnology company. The Company is engaged in the development and commercialization of therapies primarily for eye disease. The Company’s lead asset, OPT-302, is a novel biologic inhibitor of VEGF-C and VEGF-D, for use in combination with VEGF-A inhibitors for the treatment of wet age-related macular degeneration (wet AMD) and diabetic macular edema (DME). The Company’s principal activities include the progression of the Company’s Phase III registration trials of OPT-302 for wet AMD. It also manufactures OPT-302 for use in Phase III clinical trials, conducts activities to support the commercialization of the product and expanded its management team in the United States to facilitate broader oversight and execution of its Phase III program. The Company’s development activities are based on an intellectual property portfolio covering key targets (Vascular Endothelial Growth Factors VEGF-C, VEGF-D and VEGF Receptor-3).

Contact Information

Headquarters

Suite 0403 Level 4, 650 Chapel Street, South YarraMELBOURNE, VIC, Australia 3141

Phone

---

Fax

---

Executives

Non-Executive Independent Chairman of the Board

Jeremy Levin

Chief Executive Officer

Frederic Guerard

Chief Financial Officer

Peter Lang

Senior Vice President - Clinical Development

Julie Clark

Senior Vice President - Global Clinical Operations

Bruno Gagnon